2nd International Conference on Fostering Interdisciplinary Research In Health Sciences (ICFIRHS) 2019 (01-May-2019)        |

Journal :   Research Journal of Pharmacy and Technology

Volume No. :   12

Issue No. :  5

Year :  2019

Pages :   2160-2166

ISSN Print :  0974-3618

ISSN Online :  0974-360X


Registration

Allready Registrered
Click to Login

Molecular Docking of N-benzoyl-N'-(4-fluorophenyl) thiourea Derivatives as Anticancer Drug Candidate and Their ADMET prediction



Address:   Suko Hardjono1, Tri Widiandani1*, Bambang T. Purwanto1, Anindi L. Nasyanka2
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60286, Indonesia
2Delima Persada School of Health Sciences, Gresik, Indonesia
*Corresponding Author
DOI No: 10.5958/0974-360X.2019.00359.7

ABSTRACT:
The pharmacophore group found in N-benzoyl-N’-(4-fluorophenyl) thiourea is the same as the urea derivative which has anti-cancer activity, such as hydroxyurea. Because of the presence of these pharmacophore groups, this compound is worthy of being used as parent compound for further development through structural modification. Structural modification as an effort to design the new drug is done by changing the substituted group, which will cause changes in physicochemical properties. The change in physicochemical properties can affect the pharmacokinetics process, toxicity and activity of each compound that can be predicted through molecular modeling. The aims of this present study are to obtain the N-benzoyl-N'-(4-fluorophenyl) thiourea derivatives which is predicted to have the best anticancer activity and is not toxic based on the in silico approach. One of the mechanism of action of the N-benzoil- N'-(4-fluorophenyl) thiourea derivative as an anti-cancer is to inhibit the Sirtuin1 enzyme (SIRT1). The inhibition of the enzyme causes over expression of p53 which is the gene responsible for negative regulation of the cell cycle by using the Chem Bio Draw Ultra 13.0 program which can predict physico-chemical properties of Log P, MR and Etot. Pharmacokinetic properties (ADME) and toxicity were determined using the online pkCSM program. The in silico test is carried out by documenting compounds which will be predicted by the target enzyme SIRT1 with PDB ID: 4I5I. Documentation results in the form of bond energy which is illustrated by the value of the Rerank Score (RS), using the MVD program (Molegro Virtual Docker). Compounds that have small RS values are predicted to have a large activity. From the results of the in silico test using the MVD program and the online pkCSM program it can be seen that 4 (four) N-benzoyl-N'-(4-fluorophenyl)thiourea derivatives are predicted to have good pharmacokinetics (ADME) properties, causing relatively low toxicity except N-4-trifluoromethyl-benzoyl-N’-(4-fluorophenyl)thiourea which can cause hepatotoxics. All compounds have cytotoxic activity greater than the comparative ligand 4I5_601. Compounds of N-4-chlorobenzoyl-N'-(4-fluorophenyl) thiourea are compounds that are predicted to have the most activity and are not toxic.
KEYWORDS:
Molecular modeling, N-benzoyl-N’-(4-fluorophenyl) thiourea, Physico-chemistry, ADME prediction.
Cite:
Suko Hardjono, Tri Widiandani, Bambang T. Purwanto, Anindi L. Nasyanka. Molecular Docking of N-benzoyl-N'-(4-fluorophenyl) thiourea Derivatives as Anticancer Drug Candidate and Their ADMET prediction. Research J. Pharm. and Tech. 2019; 12(5):2160-2166.
[View HTML]     



Visitor's No. :   560718